Preparation of [In-111]-labeled-DTPA-bombesin conjugates at high specific activity and stability: Evaluation of labeling parameters and potential stabilizers

Applied Radiation and Isotopes

Volumn 70, Issue 5, 2012, Pages 856-863

  Pujatti, P B ^a   Massicano, A V F ^a   Mengatti, J ^a   de Araujo E B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bombesin conjugates; High specific activity; Indium 111; Radiolabeling; Stabilizers

Indexed keywords

BOMBESIN CONJUGATES; INDIUM-111; RADIOCHEMICAL PURITY; RADIOLABELING; ROOM TEMPERATURE; SPECIFIC ACTIVITY;

EMPENNAGES; INDIUM; PEPTIDES; RADIATION CHEMISTRY;

STABILITY;

BOMBESIN; PENTETATE INDIUM IN 111;

ARTICLE; CONJUGATION; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MOLECULAR STABILITY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOLYSIS; REACTION TIME; ROOM TEMPERATURE; THIN LAYER CHROMATOGRAPHY;

BOMBESIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; INDIUM RADIOISOTOPES; PENTETIC ACID;

EID: 84858342277     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2012.02.064     Document Type: Article

References (24)

1. Anastasi A., Erspamer V., Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the european amphibians Bombina and Alytes. Experientia 1970, 27:166-167.
2. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002, 43(12):1650-1656.
3. 177Lu]Lu-AMBA, a systemic radiotherapeutic agent for gastrin releasing peptide receptor positive tumors. Appl. Radiat. Isot. 2008, 66:497-505.
4. 99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor positive tumors. Q. J. Nucl. Med. Mol. Imaging 2007, 51:42-50.
5. 2 structural paradigm in a prostate cancer model. Bioconjugate Chem. 2008, 19:1803-1812.
6. Gugger M., Reubi J.C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 1999, 155(6):2067-2076.
7. 4]-bombesin analog in human prostate tumor-bearing mice. Cancer Biother. Radiopharm. 2009, 24(4):435-443.
8. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J. Nucl. Med. 2011, 52(2):270-278.
9. 2. Nucl. Med. Biol. 2002, 29(4):423-430.
10. Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev. 2008, 60(1):1-42.
11. 2], in a prostate tumor xenografted mouse model. Nucl. Med. Biol. 2010, 37:751-761.
12. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J. Nucl. Med. 2006, 47(7):1144-1152.
13. 90Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjugate Chem. 2001, 12:554-558.
14. Liu S., Ellars C.E., Edwards D.S. Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. Bioconjugate Chem. 2003, 14:1052-1056.
15. Liu Z., Yan Y., Liu S., Wang F., Chen X. 68)Ga-labeled NOTA-RGD-bombesin peptide for dual integrin and GRPR-targeted tumor imaging. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(9):1483-1494.
16. Maina T., Nock B.A., Zhang H., Nikolopoulou A., Waser B., Reubi J.C., Maecke H.R. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J. Nucl. Med. 2005, 46:823-830.
17. Markwalder R., Reubi.J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999, 59(5):1152-1159.
18. 177Lu-labeled bombesin derivatives with amino acidic spacers for selective targeting of human PC-3 prostate tumor cells. Q. J. Nucl. Med. Mol. Imaging 2011, 55(3):310-323.
19. Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J. Nucl. Med. 2008, 49(11):1735-1738.
20. Schroeder R.P.J., Müller C., Reneman S., Melis M.L., Breeman W.A.P., Blois E., Bangma C.H., Kreening E.P., Van Werden W.M., de Jong M. A standarised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(7). pp. 3186-1396.
21. Vallabhajosula S., Killeen R.P., Osborne J.R. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological and pharmacologic factors. Semin. Nucl. Med. 2010, 40:220-241.
22. 177Lu-DOTA-PESIN). Cancer Res. 2011, 71(3):1009-1018.
23. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., Maecke H.R. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004, 64:6707-6715.
24. Zhang H., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., Maecke H.R. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1198-1208.